We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Affordable POC Tests to Improve Early Cancer Detection in Low-Resource Settings

By LabMedica International staff writers
Posted on 31 Oct 2023

Cancer ranks as the first or second leading cause of early death in 134 out of 183 countries. More...

Forecasts suggest that the global rate of cancer cases will surge by 50% between 2018 and 2040. This increase is expected to be more pronounced in countries with fewer resources and inadequate healthcare infrastructure to manage cancer effectively. While early detection and proper treatment can cure most types of cancer, existing diagnostic tests are often too complex or costly to be used in basic healthcare settings, especially in areas with limited medical services. Now, new point-of-care (POC) technologies for early cancer detection aim to bring healthcare services closer to the patient, making treatment timelier and more accessible, which could enhance outcomes in the long run.

Rice University (Houston, TX, USA) is leading a multinational collaboration, involving engineers, cancer specialists, and global health experts from three different continents. The research group has received a grant for up to five years from the National Institutes of Health to set up a leading research facility within the Texas Medical Center. The focus will be on creating cost-effective POC technologies for early cancer detection in both the United States and other nations lacking sufficient healthcare infrastructure. Named the Center for Innovation and Translation of POC Technologies for Equitable Cancer Care (CITEC), the center will operate under the umbrella of the Rice360 Institute for Global Health Technologies. Funded initially by a USD 1.3 million grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the center could receive up to USD 6.5 million over the next five years. CITEC will primarily focus on the development of POC diagnostics for oral, cervical, and gastrointestinal cancers.

“CITEC will identify needed technologies, accelerate their development, evaluate their performance and impact in diverse settings and train local users and technology developers to create and disseminate more equitable POC technologies,” said Sharmila Anandasabapathy is vice president of global health at Baylor College of Medicine.

Related Links:
Rice University


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic CLIA Analyzer
Shine i9000
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.